Gilead (GILD) to Acquire HOOK for $10 million
Gilead Sciences Inc. (NASDAQ:GILD) commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Gilead Sciences Inc. (GILD)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 5,451,143 | $610,800,573 | +3% | 0.92% |
| 2. | Citadel Investment Group Ken Griffin | 5,373,962 | $602,152,442 | +15% | 0.11% |
| 3. | Millennium Management Israel Englander | 2,538,504 | $284,439,373 | +272% | 0.15% |
| 4. | Holocene Advisors Brandon Haley | 2,307,871 | $258,596,946 | 0.75% | |
| 5. | AQR Capital Management Cliff Asness | 1,864,670 | $207,369,860 | +3% | 0.21% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $99.92 | 10,000 | Director | 88,173 | 2015-02-06 | Filing | |
| $43.05 | 10,000 | Director | 69,458 | 2013-02-28 | Filing | |
| $44.00 | 10,000 | Director | 26,097 | 2012-02-22 | Filing | |
| $38.60 | 8,704 | Director | 12,800 | 2010-05-04 | Filing | |
| $38.59 | 4,096 | Director | 4,096 | 2010-05-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $107.52 | 3,000 | Officer | 121,152 | 2025-05-22 | Filing | |
| $107.52 | 12,500 | Officer | 124,152 | 2025-05-22 | Filing | |
| $107.52 | 12,500 | Officer | 124,152 | 2025-05-22 | Filing | |
| $99.82 | 2,500 | Officer | 165,674 | 2025-05-15 | Filing | |
| $106.40 | 2,500 | Officer | 168,174 | 2025-04-15 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 117,470,825 | $13,162,605,942 | 0.24% | |
| 2. | 116,104,572 | $13,009,517,311 | 0.27% | |
| 3. | 59,523,675 | $6,669,627,784 | 0.27% | |
| 4. | 58,542,842 | $6,559,725,439 | 0.42% | |
| 5. | 54,610,370 | $6,119,089,714 | 1.33% |
News See All
10 Unstoppable Dividend Stocks to Buy Now
Dividend-paying stocks are drawing increased attention from investors amid this year’s market volatility.
Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now
Domestic manufacturing in the pharmaceutical industry has fallen considerably in the last decades, with most active ingredient production moving to China and other countries.
15 Best Stocks to Buy According to Jim Simons' Renaissance Technologies
Even after his passing in 2024, billionaire investor and mathematician Jim Simons remains known as the "Quant King" of hedge funds due to the extraordinary success of Renaissance Technologies, his quantitative...
Gilead Sciences, Inc. (NASDAQ:GILD) Q1 2025 Earnings Call Transcript
Rebecca: Good afternoon, everyone. And welcome to Gilead Sciences, Inc.'s First Quarter 2025 Earnings Conference Call. My name is Rebecca, and I'll be today's host.
11 Cheap NASDAQ Stocks to Buy According to Hedge Funds
On April 10, Dan Ives, Head of Global Tech Research at Wedbush Securities, appeared on an interview at CNBC and expressed that the tech sector could be heading into a period of major volatility.
11 Most Undervalued Quality Stocks to Buy Now
On February 24, Kayne Anderson Rudnick chief market strategist Julie Biel joined 'The Exchange' on CNBC to discuss her thoughts on how good quality companies can ride out turbulence in the market.
Multiple Tailwinds Lifted Gilead Sciences (GILD) in Q1
ClearBridge Investments, an investment management company, released its “ClearBridge Value Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here.
7 Most Undervalued Biotech Stocks To Invest In
On February 21, Jared Holz, Mizuho Securities America's healthcare sector strategist, appeared on CNBC to discuss Trump's tariffs and their effects on the American pharma sector.
Billionaire Hedge Funds
